Novel mutant-selective EGFR kinase inhibitors against EGFR T790M [PDF]
Nature, 2009 The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity ...
Zhou, Wenjun +14 more
openaire +3 more sources
Long-term lithium treatment in bipolar disorder. effects on glomerular filtration rate and other metabolic parameters [PDF]
, 2017 .BACKGROUND: Concerns about potential adverse effects of long-term exposure to lithium as a mood-stabilizing treatment notably include altered renal function.
Abramowicz, Maria +26 more
core +3 more sources
Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]
, 2010 The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp +3 more
core +1 more source
Hittite Journal of Science and Engineering, 2023 Cancer, defined as the uncontrolled growth and proliferation of cells, is a serious disease seen in many people around the world. For this reason, a lot of work has been done and continues to be done by scientists for the diagnosis and treatment of ...
Serda Kecel Gunduz, Bilge Bıçak
doaj +1 more source
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Seminars in Cancer Biology, 2020 Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 deletions and the L858R point mutation) comprise the vast majority of EGFR ...
Peter T. Harrison +2 more
semanticscholar +1 more source
Journal for ImmunoTherapy of Cancer, 2022 Backgrounds Immunotherapy is less effective in patients with epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC). Lower programmed cell death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB) are reported to be the
Lei Yang +12 more
semanticscholar +1 more source
GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. [PDF]
, 2016 Abnormal activation of the epidermal growth factor receptor (EGFR) due to a deletion of exons 2-7 of EGFR (EGFRvIII) is a common alteration in glioblastoma (GBM). While this alteration can drive gliomagenesis, tumors harboring EGFRvIII are heterogeneous.
David James, C +11 more
core +1 more source
Hydroxygenkwanin Suppresses Non-Small Cell Lung Cancer Progression by Enhancing EGFR Degradation
Molecules, 2020 Epidermal growth factor receptor (EGFR) is frequently overexpressed and mutated in non-small cell lung cancer (NSCLC), which is the major type of lung cancer.
Yann-Lii Leu +6 more
doaj +1 more source
Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. [PDF]
, 2015 We hypothesized that aberrations activating epidermal growth factor receptor (EGFR) via dimerization would be more sensitive to anti-dimerization agents (e.g., cetuximab).
Bazhenova, Lyudmila +6 more
core +3 more sources
Nature Communications, 2021 Glioblastoma (GBM) is the most common type of adult malignant brain tumor, but its molecular mechanisms are not well understood. In addition, the knowledge of the disease-associated expression and function of YTHDF2 remains very limited.
Runping Fang +11 more
semanticscholar +1 more source